Bifidobacterium lactis Probio-M8 ameliorated the symptoms of type 2 diabetes mellitus mice by changing ileum FXR-CYP7A1

Abstract

Abstract The aim of this study was to investigate the effect of Bifidobacterium lactis Probio-M8 on glucolipid metabolism and gut microbiota (GM) composition in type 2 diabetes mellitus (T2DM) mice. The glucolipid metabolic profiles were analyzed. The 16S rRNA gene sequencing was employed to investigate GM. The levels of farnesyl X receptor (FXR) and cytochrome p450 7A1 (CYP7A1) were detected by quantitative polymerase chain reaction and western blot assays. The total bile acids (TBAs), ceramide (CE), glucagon-like peptide-1 (GLP-1), and fibroblast growth factor (FGF)-15 were also detected. The morphological features of liver and pancreas were also analyzed. Compared with the model group, Probio-M8 restored body weight, food intake and water intake, as well as improved hyperglycemia symptoms, serum glucolipid parameters, and the composition of intestinal microbes in T2DM diabetic mice. Moreover, the reduced level of FXR and the increased level of CYP7A1 in T2DM mice were reversed by Probio-M8 treatment. The increased levels of TBA and CE and the reduced levels of GLP-1 and FGF-15 in T2DM mice were altered after Probio-M8 stimulation. Besides, the altered morphology of liver and ileum in T2DM mice was alleviated by Probio-M8 treatment. Taken together, we suggested that the symptoms of T2DM could be ameliorated by Probio-M8 in T2DM mice.